近岸蛋白(688137.SH):2024年度淨虧損5480.68萬元
格隆匯2月27日丨近岸蛋白(688137.SH)公佈2024年度業績快報,報告期內,公司實現營業總收入12,744.70萬元,同比下降16.81%;實現歸屬於母公司所有者的淨利潤-5,480.68萬元,同比下降526.72%;實現歸屬於母公司所有者的扣除非經常性損益的淨利潤-7,221.41萬元。
報告期內,公司不斷豐富靶點蛋白、細胞因子、重組抗體、酶及試劑產品線,持續完善並強化針對細分應用市場的全流程解決方案。持續受外部環境、市場需求變化及行業週期性調整影響,公司產品銷售結構發生變化。公司爲進一步夯實重組蛋白核心競爭力,持續加大產品質量提升的相關投入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.